Clinical Report: FDA Approves Novel Antibiotic for cIAI

Overview

The FDA has approved aztreonam-avibactam in combination with metronidazole for adults with complicated intra-abdominal infections (cIAI) who lack alternative treatment options. This approval is the first combination of a monobactam and a beta-lactamase inhibitor.

Background

The rise of antimicrobial resistance among gram-negative bacteria has created a need for new treatment options. Complicated intra-abdominal infections often lead to extended hospital stays and increased morbidity. Aztreonam-avibactam targets specific resistant pathogens.

Data Highlights

Key Findings

• Aztreonam-avibactam is indicated for infections caused by susceptible gram-negative microorganisms.
• The approval was based on data from the phase III REVISIT trial involving 312 patients.
• Common adverse reactions included hepatic adverse reactions, anemia, diarrhea, hypokalemia, and pyrexia.
• Monitoring for hypersensitivity reactions and liver function is recommended during treatment.
• The drug is contraindicated in patients with known hypersensitivity to aztreonam or avibactam.

Clinical Implications

Regular monitoring for adverse reactions and liver function is essential, particularly in patients with pre-existing liver conditions.

Conclusion

The approval of aztreonam-avibactam is a new option for treating complicated intra-abdominal infections.

Related Resources & Content

1. FDA, FDA News Release, 2024 -- FDA Approves Novel Antibiotic for cIAI
2. The Surgical Infection Society, 2024 -- The Surgical Infection Society Guidelines on the Management of Intra-Abdominal Infection: 2024 Update
3. ScienceDirect, 2024 -- Aztreonam–avibactam versus meropenem for the treatment of serious infections caused by Gram-negative bacteria (REVISIT)
4. conexiant — FDA Approves Cefepime-Zidebactam Injection
5. International Journal of Infectious Diseases — Successful eravacycline monotherapy for cefiderocol-resistant Acinetobacter baumannii bloodstream infection in a critically ill patient with concomitant Clostridioides difficile colitis
6. conexiant — FDA Approves New UTI Treatment for Women
7. Infection — Emerging Antibiotics: Are We Still in the Transitional Phase of the Antibiotic Era?
8. FDA Approves Cefepime-Zidebactam Injection
9. Successful eravacycline monotherapy for cefiderocol-resistant Acinetobacter baumannii bloodstream infection
10. FDA Approves New UTI Treatment for Women
11. EMBLAVEO (aztreonam and avibactam) Highlights of Prescribing Information
12. The Surgical Infection Society Guidelines on the Management of Intra-Abdominal Infection: 2024 Update
13. Aztreonam–avibactam versus meropenem for the treatment of serious infections caused by Gram-negative bacteria (REVISIT): a descriptive, multinational, open-label, phase 3, randomised trial - ScienceDirect